A Whole New World in Inflammatory Bowel Disease: Embracing Novel Horizons with Intravenous Iron
Gastroenterologists and other members of the multidisciplinary interprofessional IBD care team of surgeons, nurse practitioners/nurses, physician assistants, and pharmacists.
- Discuss the basic principles of iron metabolism and absorption, including the practical distinctions between functional and absolute iron deficiency, with a focus on how these principles apply to IDA treatment in IBD.
- Understand the prominent role of iron deficiency as an etiology for anemia in IBD, and evaluate the role of inflammation and elevated hepcidin levels on iron supplementation strategies.
- Recognize the prevalence and incidence patterns of comorbid IBD and IDA, and describe the substantial impact of anemia on IBD patient quality-of-life and clinical outcomes.
- Review the essential utility of serum ferritin, transferrin saturation (TSAT), and C-reactive protein as diagnostic laboratory indices, alongside hemoglobin, for IDA in IBD, and integrate the “diagnose, treat-to-target, and rapid reassessment cycle” into practice.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for IDA management in IBD, and identify how the innovative nanocolloidal design of next-generation IV iron products dramatically improves upon the safety and efficacy profiles of high-molecular weight (HMW) dextran agents, with anaphylaxis rates as low as 0.1%.
- Interpolate the expanding scientific evidentiary base regarding the impact of inflammation and hepcidin on iron availability and utilization, especially in an intrinsically hyperinflammatory condition like IBD, and the resultant rationale for preferential treatment with IV iron vs. oral iron.
- Examine the natural history of IV iron products, the relevance of nanoparticle drug design, and distinguish among the FDA-approved IV iron agents, including the nuances that yield unique clinical utility and impact.
- Design and employ an evidence-based algorithm that incorporates diagnosis, evaluation, and treatment of IDA in IBD, and engage in a highly interactive expert roundtable discussion of diverse and illustrative patient cases.
Gary R. Lichtenstein, MD (Activity Chair)
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Millie D. Long, MD, MPH
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Director of Fellowship Program
University of North Carolina
Chapel Hill, NC
Stephen B. Hanauer, MD
Professor of Medicine